Sfoglia per Autore
P. 11.17: The Role of Adherence to Therapy on the Outcome in Inflammatory Bowel Disease
2017-01-01 Astegiano, M; Vernero, M; Finocchiaro, F; Reggiani, S; Ribaldone, D; Sapone, N; Bertolusso, L; Pellicano, R
Diagnostic delay: assessment, improvement and outcome consequences in inflammatory bowel disease
2019-01-01 Vernero, M; Ribaldone, DG; Astegiano, M
Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients
2019-01-01 Ribaldone D.G.; Vernero M.; Parisi S.; Ditto M.C.; Pellicano R.; Morino M.; Saracco G.M.; Fusaro E.; Astegiano M.
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index
2019-01-01 Ribaldone D.G.; Caviglia G.P.; Pellicano R.; Vernero M.; Italia A.; Morino M.; Saracco G.M.; Astegiano M.
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease
2020-01-01 Vernero M.; Ribaldone D.G.; Cariti C.; Ribero S.; Susca S.; Astegiano M.; Dapavo P.
Efficacy of a preparation based on calcium butyrate, bifidobacterium bifidum, bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study
2021-01-01 Caviglia G.P.; De Blasio F.; Vernero M.; Armandi A.; Rosso C.; Saracco G.M.; Bugianesi E.; Astegiano M.; Ribaldone D.G.
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
2022-01-01 Armandi A.; Rosso C.; Nicolosi A.; Caviglia G.P.; Abate M.L.; Olivero A.; D'amato D.; Vernero M.; Gaggini M.; Saracco G.M.; Ribaldone D.G.; Leeming D.J.; Gastaldelli A.; Bugianesi E.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile